Overview
The goal of this clinical trial is to compare CXL with combined treatment with CXL and t-PTK.
The main questions it aims to answer are whether combined treatment can give better visual acuity and if the treatments are equally safe.
Eligibility
Inclusion Criteria:
- Patients must be 18 years or older at the time of signing the informed consent form. There is no upper age limit.
- Progressive keratoconus with indication for CXL
- Corneal thickness ≥ 420 μm
Exclusion Criteria:
- Other eye disease causing visual impairment